Food News and Research

RSS

New textbook provides facts and dispels myths on sugar/fructose consumption

A new textbook, Fructose, High Fructose Corn Syrup, Sucrose and Health, published this month by Springer Press, under their Humana Press imprint, provides one of the most comprehensive scientific analyses on the closely-watched issue of caloric sweetener consumption.

1 Apr 2014

Scientists develop new procedure using ultrasound energy to "ablate" prostate cancer

Men with prostate cancer face tough choices: when, or even if, to treat their cancer; what procedure to use; and how to balance their chosen treatment with their quality of life. Now, a new multicenter clinical trial seeks to offer men another option - one that physicians hope will treat prostate cancers with fewer side effects.

1 Apr 2014

Study aims at increasing vegetable consumption among kids

As part of the European project HabEat (2010-2014), coordinated by INRA and involving 10 scientific partners, researchers have made a step forward in the understanding of how eating behaviours and preferences form in early life. On March 31st and April 1st in Dijon (France), a symposium presents the results and recommendations for early childhood professionals and parents.

1 Apr 2014

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy.

31 Mar 2014

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma.

31 Mar 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.

31 Mar 2014

Pfizer issues statement on FDA approval of non-prescription drug, Nexium 24HR

Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium® 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.

31 Mar 2014

Carb breakdown gene linked to obesity, researchers find

Researchers at King's College London and Imperial College London have discovered that people with fewer copies of a gene coding for a carb-digesting enzyme may be at higher risk of obesity. The findings, published in Nature Genetics, suggest that dietary advice may need to be more tailored to an individual's digestive system, based on whether they have the genetic predisposition and necessary enzymes to digest different foods.

31 Mar 2014

Celiac disease people may have near two-fold increased risk of coronary artery disease

People with celiac disease may have a near two-fold increased risk of coronary artery disease compared with the general population, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.

31 Mar 2014

Actavis gets favorable ruling in patent suit against generic Lialda

Actavis plc today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent).

29 Mar 2014

Stigmatization may do more harm than good for modern humans, say researchers

Stigmatization may have once served to protect early humans from infectious diseases, but that strategy may do more harm than good for modern humans, according to Penn State researchers.

29 Mar 2014

New -7 million centre to lead research in manufacturing advanced chemical products

A new -7 million centre at the University of Leeds will lead UK research in manufacturing advanced chemical products. The Centre for Doctoral Training (CDT) in Complex Particulate Products and Processes will fund 50 new research students in a field that has been targeted by the Government as a key growth area for the UK economy.

29 Mar 2014

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.

29 Mar 2014

TV watching leads to excessive snacking, cardiovascular risk in middle school kids

Middle school kids who park themselves in front of the TV for two hours or more each day are more likely to consume junk food and have risk factors for cardiovascular disease, even compared to those who spend an equal amount of time on the computer or playing video games, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session.

29 Mar 2014

Food News and Research

New textbook provides facts and dispels myths on sugar/fructose consumption

Scientists develop new procedure using ultrasound energy to "ablate" prostate cancer

Study aims at increasing vegetable consumption among kids

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

FDA approves additional manufacturing suite for Pacira’s EXPAREL

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

Pfizer issues statement on FDA approval of non-prescription drug, Nexium 24HR

Carb breakdown gene linked to obesity, researchers find

Celiac disease people may have near two-fold increased risk of coronary artery disease

Actavis gets favorable ruling in patent suit against generic Lialda

Stigmatization may do more harm than good for modern humans, say researchers

New -7 million centre to lead research in manufacturing advanced chemical products

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

TV watching leads to excessive snacking, cardiovascular risk in middle school kids

The future is bioengineered: Synthetic biology and global sustainability eBook

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Latest News